TD Cowen named Xenon Pharmaceuticals (XENE) a Best Idea for 2025 while keeping a Buy rating on the shares with no price target After a quiet 2024, Xenon is poised to deliver azetukalner Phase III data for focal onset seizures in the second half of 2025, the analyst tells investors in a research note. The firm says its key opinion leaders have been very supportive of the Phase. II data, and have high hopes for success in Phase III and eventual uptake.
Education
About Us
Working with TipRanks
Follow Us
1